Lantheus Holdings Inc (LNTH) Stock AnalysisLNTHStock AnalysisLantheus Holdings Inc

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Lantheus Holdings Inc is currently trading at $100.77, just below the acquisition offer of $102.50 per share from Curium, which includes potential additional cash payments of up to $12.00 per share. This represents a 38% premium over its 60-day average price, indicating strong market confidence. However, the recent downgrades from multiple analysts to Hold suggest that the stock is no longer trading on fundamentals but rather on the acquisition terms, which introduces uncertainty about future price movements. The RSI is at 51.55, indicating a neutral momentum, and the stock has seen a year-to-date change of +49.80%, reflecting strong past performance but also potential overvaluation given the acquisition context.

4 analysts cover LNTH: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 82.17.